HOLX advances breast health with AI tools like Genius Detection PRO and the upcoming Envision 3D platform.
The latest trading day saw Hologic (HOLX) settling at $63.26, representing a -2.1% change from its previous close.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
In the latest trading session, Hologic (HOLX) closed at $65.85, marking a +1.46% move from the previous day.
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
In the most recent trading session, Hologic (HOLX) closed at $65.11, indicating a +1.31% shift from the previous trading day.
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) concluded the recent trading session at $64.14, signifying a -1.6% move from its prior day's close.